174 related articles for article (PubMed ID: 16616575)
21. Bisphosphonates and metabolic bone disease in the ICU.
Hollander JM; Mechanick JI
Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):190-5. PubMed ID: 19209471
[TBL] [Abstract][Full Text] [Related]
22. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
[TBL] [Abstract][Full Text] [Related]
23. Abnormal bone remodelling in inflammatory arthritis.
Bogoch ER; Moran E
Can J Surg; 1998 Aug; 41(4):264-71. PubMed ID: 9711159
[TBL] [Abstract][Full Text] [Related]
24. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
[TBL] [Abstract][Full Text] [Related]
25. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
Romas E
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
[TBL] [Abstract][Full Text] [Related]
27. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
Tanaka Y
Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate rescue in distraction osteogenesis: a case series.
Kiely P; Ward K; Bellemore C M; Briody J; Cowell CT; Little DG
J Pediatr Orthop; 2007 Jun; 27(4):467-71. PubMed ID: 17513972
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers.
Garnero P; Delmas PD
Curr Opin Rheumatol; 2004 Jul; 16(4):428-34. PubMed ID: 15201607
[TBL] [Abstract][Full Text] [Related]
30. Bone safety of low-dose glucocorticoids in rheumatic diseases.
Saag KG
Ann N Y Acad Sci; 2014 May; 1318():55-64. PubMed ID: 24815076
[TBL] [Abstract][Full Text] [Related]
31. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Morris GJ; Mitchell EP
J Natl Med Assoc; 2007 Jan; 99(1):35-45. PubMed ID: 17304967
[TBL] [Abstract][Full Text] [Related]
33. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?
Amoroso V; Petrelli F; Pedersini R; Simoncini EL; Clézardin P; Barni S; Berruti A
Future Oncol; 2015; 11(21):2853-6. PubMed ID: 26403833
[No Abstract] [Full Text] [Related]
35. Potential for bisphosphonate treatment in Legg-Calve-Perthes disease.
Little DG; Kim HK
J Pediatr Orthop; 2011 Sep; 31(2 Suppl):S182-8. PubMed ID: 21857436
[TBL] [Abstract][Full Text] [Related]
36. Effect of oral clodronate on structural damage and bone turnover in rheumatoid arthritis.
Valleala H; Laasonen L; Koivula MK; Risteli J; Konttinen YT
Clin Exp Rheumatol; 2012; 30(1):114-7. PubMed ID: 22260818
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
Drake MT; Cremers SC
Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate and Implant Dentistry - Is it Safe?
Thirunavukarasu A; Pinto HG; Seymour KG
Prim Dent J; 2015 Aug; 4(3):30-3. PubMed ID: 26556516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
